EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

SF3A3 Drives Tumorigenesis in Endometrial Cancer by Enhancing c‐FOS Expression and Represents a Potential Therapeutic Target

Wei Yu, Yi Gu, Hengrui Zhang, Wunan Huang, Lei Sun, Liangjian Ma, Xiaolei Liang, Lexin Liu, Guiping Chen, Weihua Wang, Zhongkai Cao, Xue Li und 2 weitere

Advanced Science · 2025

DOI: 10.1002/advs.202504184 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advanced Science, 2025. Verfasst von Wei Yu und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephrology, Children's Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health, Hangzhou, …. Hauptthemen laut MEDLINE: Endometrial Neoplasms, Proto-Oncogene Proteins c-fos, RNA Splicing Factors, Carcinogenesis. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aberrant alternative splicing plays a crucial role in tumorigenesis. Here, splicing factor 3A subunit 3 (SF3A3) is significantly upregulated in endometrial cancer (EC) tissues and associated with poor prognosis. Functionally, SF3A3 drives tumor progression by promoting cell proliferation, suppressing apoptosis, and enhancing cisplatin resistance in vitro and in vivo. Mechanistically, SF3A3 regulates alternative splicing of fos proto‐oncogene, AP‐1 transcription factor subunit (c‐FOS), an oncogene linked to chemoresistance, resulting in a ≈2‐fold increase in full‐length c‐FOS expression and activation of downstream anti‐apoptotic pathways. Notably, phenylethyl isothiocyanate (PEITC) as a direct inhibitor of SF3A3 through database screening and biophysical validation via surface plasmon resonance and mass spectrometry is identified. PEITC reduces c‐FOS expression and induces apoptosis in EC cells. Moreover, encapsulating PEITC in a hydrogel delivery system significantly enhances its therapeutic efficacy by enabling controlled release, reducing dosing frequency, and improving clinical applicability. The therapeutic potential of SF3A3 inhibition is further validated using patient‐derived tumor‐like cell clusters (PTCs), where PEITC and the c‐FOS inhibitor T‐5224 exhibit synergistic effects in suppressing EC. Collectively, our findings establish SF3A3 as a novel oncogenic regulator in EC and highlight PEITC, particularly in its hydrogel formulation, as a promising therapeutic strategy for improving clinical outcomes in EC patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Endometrial NeoplasmsProto-Oncogene Proteins c-fosRNA Splicing FactorsCarcinogenesisFemaleHumansProto-Oncogene MasMiceCell Line, TumorAnimalsGene Expression Regulation, NeoplasticCell ProliferationApoptosisIsothiocyanates

Stichwörter der Autor:innen

PEITCSF3A3c‐FOSendometrial cancertumor progression

Substanzen

Proto-Oncogene Proteins c-fosProto-Oncogene MasMAS1 protein, humanRNA Splicing FactorsFOS protein, humanIsothiocyanatesphenethyl isothiocyanate

Autor:innen und Institutionen

  • Department of Nephrology, Children's Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health, Hangzhou, 310052, China.
  • The First Affiliated Hospital of Zhejiang Chinese Medical University, Zhejiang Provincial Hospital of Traditional Chinese Medicine, Hangzhou, 310028, China.
  • Eye Institute of Shandong First Medical University, State Key Laboratory Cultivation Base, Shandong Provincial Key Laboratory of Ophthalmology, Qingdao, 266071, China.
  • The First Hospital of Lanzhou University, Key Laboratory of Gynecologic Oncology, Gansu Province, Lanzhou, Gansu, 730030, China.
  • Shandong Provincial Key Laboratory of Animal Cell and Developmental Biology, School of Life Sciences, Shandong University, Qingdao, 266237, China.
  • Engineer Center of Pharmaceutical Technology, Tsinghua University, Beijing, 10084, China.

ORCID-Profile: Lidan Hu

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Yu, W., Gu, Y., Zhang, H., Huang, W., Sun, L., Ma, L., Liang, X., Liu, L., Chen, G., Wang, W., Cao, Z., Li, X., Chen, X., & Hu, L. (2025). SF3A3 Drives Tumorigenesis in Endometrial Cancer by Enhancing c‐FOS Expression and Represents a Potential Therapeutic Target. Advanced Science. https://doi.org/10.1002/advs.202504184

Vancouver

Yu W, Gu Y, Zhang H, Huang W, Sun L, Ma L, et al. SF3A3 Drives Tumorigenesis in Endometrial Cancer by Enhancing c‐FOS Expression and Represents a Potential Therapeutic Target. Advanced Science. 2025. doi:10.1002/advs.202504184

BibTeX
@article{Yu2025,
  author = {Yu, Wei and Gu, Yi and Zhang, Hengrui and Huang, Wunan and Sun, Lei and Ma, Liangjian and Liang, Xiaolei and Liu, Lexin and Chen, Guiping and Wang, Weihua and Cao, Zhongkai and Li, Xue and Chen, Xiangjun and Hu, Lidan},
  title = {SF3A3 Drives Tumorigenesis in Endometrial Cancer by Enhancing c‐FOS Expression and Represents a Potential Therapeutic Target},
  journal = {Advanced Science},
  year = {2025},
  doi = {10.1002/advs.202504184}
}
Kostenlos starten →